Samara Rosenfeld

Policies must change to curb postoperative opioid overprescribing.

The implementation of teleretinal screening could improve clinic workflow.

The results do not support the transtion from usual care to stratified care for the improvement of sciatica symptoms.

Upadacitinib 15 mg and 30 mg outperformed placebo in Measure Up 2, the second part of a phase 3 study on the monotherapy.

Despite negative trial resutls, the data support the posibility of tapering off NSAIDs and the plausibility of self-management approaches like CBT.

The statement contains positions and oppositions for telemedicine, along with highlights barriers and opportunities for patients and rheumatology professionals.

Gout must be treated every day rather than as a single event.

John Botson, MD, defines gout and how it can be treated.

A clinical rheumatologist breaks down how the combination therapy can be used to treat uncontrolled gout.

The drug is well-tolerated in methotrexate inadequate response patients with rheumatoid arthritis.

Patients who cannot tolerate cDMARDs may experience additional value from tocilizumab compared to adalimumab.

More patients maintain therapeutic response when treated concomitantly with methotrexate and pegloticase when compared to those who use pegloticase alone.

A team investigated data from trials of tofacitinib, adalimumab, and placebo.

The safety profile is consistent with previous studies of the ixekizumab.

The safety profile of upadacitinib is consistent with phase 3 rheumatoid arthritis studies.

The late-breaking data reveal the safety and efficacy of upadacitinib versus placebo and adalimumab.

The incidence rate of serious infection events and opportunistic infections was higher among the upadacitinib 30 mg group than the 15 mg group.

The findings are based on data from a 24-week observation from an ongoing phase 3 PATERA study.

Patients report sustained improvements in pain and fatigue from taking ixekizumab every 2 or 4 weeks over 3 years.

The findings are important to understand treatment persistence and switch patterns in rheumatoid arthritis patients with poor prognostic factors in a real-world setting.

Findings suggest 5-10 mg of tanezumab significantly improve pain versus placebo in patients with chronic low back pain.

The results highlight a significant improvement in rheumatoid arthritis signs and symptoms for those who used upadacitinib over placebo and adalimumab.

Patients are unaffected by the switch from ADL-EU to ADL-PF.

A new study shows that biomechanical footwear improved osteoarthritis knee pain at 24 weeks as compared to patients in a control group who wore traditional footwear. The results, although statistically significant, need to be replicated to prove clinical importance, researchers reported in JAMA.

Pregnant women who took fluconazole orally had a higher risk of giving birth to a baby with muscle and bone malformation, shows a new study published in The BMJ.

Taking oral fluconazole in the first trimester is not associated with oral clefts or conotruncal malformations.

There is no significant association between biologic exposure and the development of melanoma in patients with IBD, rheumatoid arthritis, or psoriasis.

More than 300 million cases of knee and hip osteoarthritis occurred worldwide in 2017.

The recommendations put a strong focus on urate-lowering therapy for gout.

The results must be replicated to prove clinical significance.